China Merchants Capital

China Merchants Capital (CMC) is a prominent Chinese private equity firm established in 2012, operating as a joint venture between China Merchants Group (CMG) and GLP. The firm manages assets exceeding RMB 300 billion (approximately USD 41.7 billion) across 67 funds, focusing on sectors such as transportation, infrastructure, logistics, real estate, financial services, fintech, technology, advanced manufacturing, green tech, and healthcare. CMC's investment strategies encompass early-stage, growth, late-stage, buyout, turnaround, and distressed investments, reflecting its comprehensive approach to private equity. CMC's investment philosophy emphasizes collaboration with both domestic and international investors, leveraging its extensive network to identify and capitalize on strategic opportunities. The firm's diverse portfolio includes investments in media and entertainment, consumer goods, telecommunications, energy, biotechnology, pharmaceuticals, automotive, retail, education, and more. This broad industry focus enables CMC to adapt to evolving market dynamics and pursue value creation across various sectors. With a team of over 250 investment professionals operating from offices in Beijing, Shenzhen, and Hong Kong, CMC is committed to driving innovation and growth through its investments. The firm's strategic partnership with GLP enhances its capabilities in fund management, investment operations, and global fundraising, positioning CMC as a leading player in the private equity landscape. CMC's track record includes significant investments in companies such as Juventas, a biotech firm specializing in cellular immunotherapy, and Cathay Biotech, a leader in bio-based materials, demonstrating its commitment to supporting innovative and high-growth enterprises.

Strong management teams, Innovative business models, Scalable growth potential, Alignment with CMC's strategic focus areas